Multimedica S.p.A.

Running trials

• Not yet recruiting

  Study of a DPP 4 inhibitor and an SGLT2 inhibitor used together compared with each treatment alone in adults with type 2 diabetes treated with metformin.

  2025-524606-15-00· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

  NCT07481981· Phase 3· Source

• Recruiting

  An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

  NCT07365332· Phase 3· Source

• Recruiting

  AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

  NCT07194382· Phase 2· Source

• Active, not recruiting

  A clinical study of sotatercept in people with pulmonary arterial hypertension (MK-7962-038)

  2025-521970-33-00· Phase 3· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Source

• Recruiting

  An Open-Label Extension Study of Subjects who Received an Avalyn Inhaled Antifibrotic Agent

  2024-518289-28-00· Phase 2· Source

• Active, not recruiting

  A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT06795048· Phase 4· Source

• Recruiting

  A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

  NCT06659549· Phase 2· Source

• Recruiting

  A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

  NCT06541704· Phase 3· Source

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Source

• Active, not recruiting

  A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

  NCT06510816· Phase 3· Source

• Active, not recruiting

  A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

  NCT06329401· Phase 2· Source

• Recruiting

  A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  NCT06283966· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• High blood pressure3 recruiting
• Macular degeneration3 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Pulmonary arterial hypertension2 recruiting
• Type 2 diabetes2 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Active, not recruiting

  A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

  NCT06422884· Phase 2· Source

• Completed

  A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis

  2023-510249-79-00· Phase 2· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Source

• Completed

  A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

  2023-506185-31-00· Phase 2/3· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Vixarelimab Compared with Placebo in Patients with Idiopathic Pulmonary Fibrosis and in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

  2022-502828-42-00· Phase 2· Source

• Completed

  Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial – Follow Up Long Term Extension (IMPAHCT-FUL)

  NCT05557942· Phase 3· Source

• Completed

  Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis

  NCT05537025· Phase 1/2· Source

• Completed

  Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT05255991· Phase 3· Source

• Completed

  Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) or A Phase 2b/3, Randomized, Controlled, 24-week Dose Ranging and Confirmatory Study of AV-101 in Patients with PAH

  NCT05036135· Phase 2/3· Source

• Completed

  A Phase 3 Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension (PAH) Patients.

  NCT04811092· Phase 3· Source

• Completed

  A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)

  NCT04896008· Phase 3· Source

• Completed

  A Long-term Follow-up Study of Sotatercept for PAH Treatment

  NCT04796337· Phase 3· Source